Table 3 Characteristics associated with the first severe morbidity during follow-up in untreated HIV-infected children.

Overall

405

58

17.80

Age at baseline (years)

0.54

0.39

0.07

< 1

64

7

12.78

1

-

1

-

1

-

[1 - 2]

42

7

20.36

1.29

(0.47-3.58)

0.45

(0.12 - 1.64)

0.52

(0.13 - 2.01)

[2 - 5]

108

17

20.41

1.24

(0.53 - 2.91)

0.43

(0.14 - 1.31)

0.42

(0.14 - 1.32)

[5 - 10]

142

21

16.65

0.94

(0.41 - 2.15)

0.38

(0.13 - 1.14)

0.30

(0.10 - 0.97)

[10 - 15]

49

4

14.58

0.45

(0.12 - 1.70)

0.23

(0.05 - 1.02)

0.15

(0.03 - 0.66)

Immunodeficiency

0.87

0.91

0.86

No

112

29

13.61

1

-

1

-

1

-

Yes

106

15

39.24

0.84

(0.43-1.63

0.88

(0.47 - 1.65)

0.84

(0.43 - 1.63)

Unknown

98

14

18.75

0.91

(0.46 - 1.77)

1.02

(0.54 - 1.93)

1.03

(0.51 - 2.07)

Gender

0.78

0.95

0.77

Male

216

32

18.07

1

-

1

-

1

-

Female

189

26

17.46

0.93

(0.54 - 1.60)

0.91

(0.54 - 1.58)

0.91

(0.51 - 1.61)

History of a PMTCT intervention

0.11

0.19

0.05

No

267

41

21.72

1

-

1

-

1

-

Yes

65

5

7.41

0.43

(0.15 - 1. 02)

0.32

(0.06 - 1. 63)

0.16

(0.04 - 0.72)

Unknown

73

12

17.20

1.04

(0.53 - 2.02)

1.21

(0.56 - 2.59)

0.82

(0.42 - 1.59)

Mother known to be deceased

0.13

0.26

No

308

48

18.19

1

-

1

-

Yes

97

10

16.10

1.78

(0.84 - 3.14)

1.51

(0.73 - 3.09)

Cotrimoxazole prophylaxis at baseline

0.35

No

134

17

15.60

1

-

Yes

271

41

18.89

1.33

(0.73 - 2.43)

Follow-up Centre

0.05

0.14

Cepref

131

50

21.92

1

-

1

-

MTCT

92

8

8.17

0.43

(0.18 - 1)

0.45

(0.16 - 1.29)